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ABSTRACT
Engraftment syndrome (ES) has been recognized as an inflammatory condition during neutrophil recovery after
hematopoietic stem cell transplantation (HSCT) characterized by noninfectious fever and skin rash. It has been
reported to occur frequently after autologous HSCT in children and adults, and has been shown to be an inde-
pendent risk factor for increased transplant-related mortality (TRM). However, virtually no data exist on its oc-
currence after allogeneic HSCT in children. To determine incidence, predisposing factors for, and
complications of ES in a pediatric transplant cohort, we analyzed 61 consecutive recipients of a myeloablative
allogeneic HSCT for the occurrence of ES. Diagnosis of ES was established when children presented with $2
of the following symptoms within 7 days before engraftment: (1) fever .38.0C, (2) skin rash, (3) weight gain
and albumin drop, or (4) dyspnea, hypoxia, and pulmonary infiltrates. Incidence of ES in this cohort was 48%
(29 of 61). In a univariate analysis, posttransplant granulocyte-colony stimulating factor (G-CSF) administration
(P 5 .02), and high mononuclear cell count (MNC) (P 5 .002) were identified as significant risk factors predis-
posing for the development of ES. In a multiple logistic regression analysis, amphotericin B therapy (P 5 .009)
and high MNC (P 5 .004) were significant explanatory variables for ES risk. There was a slight trend toward
a higher rate of chronic GVHD (cGVHD) in patients with ES (P 5 .11). However, after a median follow-up of
9.5 years overall survival (OS) (P 5 .53) and TRM (P 5 .65) did not differ between the 2 groups. ES presenting
with fever, rash, weight gain, and pulmonary symptoms should be recognized as a frequent complication of al-
logeneic HSCT after myeloablative conditioning in children. Treatment with G-CSF, amphotericin B, and
a high nucleated cell count of the graft predisposed for the development of ES in this study. OS and TRM in
this cohort were not affected by the occurrence of ES.
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Engraftment syndrome (ES) or autoaggression
graft-versus-host (GVHD)-like syndrome describes
a characteristic constellation of symptoms that occur
during neutrophil recovery after both allogeneic and
autologous hematopoietic stem cell transplantation
(HSCT) [1]. The syndrome consistently includes
a maculopapular skin rash and noninfectious fever,
and in some definitions also weight gain and pulmo-nary edema with hypoxemia not attributable to
pulmonary hemorrhage, fluid overload, infection,
thromboembolism, or cardiac disease. Because there
is no generally accepted standard definition, the re-
ported incidence for ES has varied widely ranging
from 5% to 72% [2-14].
The pathogenesis of ES remains unknown. It is
thought that cytokines released during neutrophil re-
covery and products of neutrophil degranulation and
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injury [1,5,15,16]. The ensuing detrimental effects re-
sult in pulmonary injury where the neutrophils may be
initially trapped, noninfectious fever, and a diffuse in-
crease in capillary leakage. In autologous transplanta-
tion the skin rash mimics autoinflammatory acute
GVHD (aGVHD) [17]. Whether this rash that coin-
cides with the appearance of autoreactive T cells di-
rected at histocompatibility complex class II antigens
is because of an auto-GVHD or part of the inflamma-
tory ES remains unknown. Past observations, however,
do suggest that there is an important clinical and path-
ophysiologic overlap of ES and autologous GVHD
[17,18].
In adults, a wide variety of risk factors for the de-
velopment of ES have been identified in different stud-
ies including breast cancer as underlying disease [7,17],
a higher number of previous treatment regimens [17],
a higher number of hematopoetic cells infused
[3,4,19], peripheral blood as source of stem cells
[2,3], the use of G-CSF [2,3,19], and GM-CSF [7],
early and steep neutrophil recovery [3,4], nonmyeloa-
blative conditioning regimens [8], patient age [8],
treatment with amphotericin B [8], a female gender
[3,8], and autologous transplantation [8]. In 1 study
of reduced intensity conditioning allogeneic trans-
plants the occurrence of ES was associated with a sig-
nificantly higher transplant-related mortality (TRM)
(49% versus 16%) and shorter median survival (168
versus 418 days) [8].
In children, there are very few studies analyzing ES.
In autologous peripheral blood stem cell transplanta-
tion, ES—as defined by fever and skin rash—was re-
ported to be a frequent event occurring in 30 of 156
patients (19.2%), and was found to be the only signif-
icant variable that influenced transplant related
mortality [10,20]. In the only prospective analysis in au-
tologous peripheral blood stem cell recipients a high
number of CD341 cells/kg infused, patients trans-
planted in early phase, the type of malignancy (solid tu-
mor), and conditioning regimens other than busulfan
were risk factors for ES, which was diagnosed in 38 of
112 of patients (34%) [13]. The study of Nu¨rnberger
et al. [12] investigated exclusively the occurrence of
capillary leakage defined as weight gain unresponsive
to furosemide. This study also contained 54 allogeneic
transplantations, where an increased incidence in unre-
lated compared to related donor transplantation was
found but influence on outcome was not analyzed.
Thus, although risk factors for and outcome of ES
are well characterized in adult allogeneic and autolo-
gous HSCT, only few data exist for autologous periph-
eral blood HSCT in the pediatric setting. Data from
allogeneic pediatric transplants are virtually missing.
We therefore retrospectively analyzed 61 consecutive
allogeneic HSCT after myeloablative conditioning
performed at our center to determine incidence, pre-disposing factors, nonrelapse mortality, and survival
in a pediatric transplant cohort.
PATIENTS AND METHODS
Study Population
Sixty-one consecutive HSCT in 60 children at
a single institution from a 13-year time period from
1988 to 2001 that fulfilled the following inclusion cri-
teria were analyzed retrospectively by careful chart re-
view: (1) allogeneic transplantation, (2) myeloablative
conditioning, and (3) achievement of neutrophil en-
graftment. Disease and transplant characteristics of
the patients are shown in Table 1. T cell depletion
was carried out by CD34-positive selection with im-
munomagnetic beads (Miltenyi Biotec, Bergisch Glad-
bach, Germany) if indicated. In all other transplants no
graft manipulation was done. No patient had to be ex-
cluded because of engraftment failure. All patients
were conditioned with myeloablative chemotherapy
with or without total body irradiation or total lymph
node irradiation. All patients or their respective care-
givers had expressed written consent to data storage
Table 1. Patient, Disease, and Transplant Characteristics
No. of patients 61
Age, median (range), years 7.8 (0.5-20)
Female/male 28/33
Donor
MFD 34
MUD 19
MMFD 8
Graft source
BM 50
PB 11
T cell depletion
No 50
Yes 11
Conditioning regimen
Busulfan based 38
TBI based 23
Underlying disease
Malignant 44 (72%)
ALL 29
AML 3
CML 8
MDS 3
ALCL 1
Nonmalignant 17 (28%)
SCID 3
FHLH 2
WAS 5
Thal. 3
Other 4
ALCL indicates anaplastic large cell lymphoma; ALL, acute lym-
phoblastic leukemia; AML, acute myeloid leukemia; BM, bone
marrow; CML, chronic myeloid leukemia; FHLH, familial he-
mophagocytic lymphohistiocytosis; MDS, myelodysplastic syn-
drome; MFD, matched family donor; MMFD, mismatched
family donor; MUD, matched unrelated donor; SCID, severe
combined immunodeficiency; Thal., thalassemia; WAS, Wiskott
Aldrich syndrome.
440 I. Schmid et al.and analysis concerning their transplants. The study
was announced to the local ethics committee and ded-
icated as not requiring formal approval because of the
retrospective nature of the study.
Supportive Care
All patients were cared for in laminar air flow units
and received oral gut decontamination. Aciclovir was
given from the day of admission until discharge. Be-
cause of concerns about potential myelotoxicity cotri-
moxazole was administered until day 2 and after stable
neutrophil counts had been achieved. Empirical broad
spectrum antibiotic therapy with a third-generation
cephalosporine and aminoglycoside was initiated in
neutropenic patients at the time of the first recorded
fever of$38.5C. A glycopeptide antibiotic was added
if fever persisted for $72 hours and amphotericin B if
the fever lasted for $96 hours. Blood, stool, and urine
cultures were taken and tested for bacterial, fungal, and
viral pathogens at the onset of fever. Blood cultures
were repeated when anti-infectious therapy was aug-
mented or changed because of persistent fever. Further
investigations for infectious agents were initiated if the
patients presented specific symptoms. G-CSF was ad-
ministered at the treating physician’s discretion after it
was licensed in 1991.
GVHD Prophylaxis
GVHD prophylaxis consisted of cyclosporine A
starting on day 21 and methotrexate on days 1, 3, 6,
and 11 in all recipients of non-T cell-depleted grafts.
Trough levels of cyclosporine A were targeted to be
in the range of 100-150 ng/mL. Steroids (prednisolone
2 mg/kg/day) were initiated if clinical signs of aGVHD
grade 2 or greater occurred.
Definitions
Neutrophil engraftment was defined as the first
day on which the absolute neutrophil count exceeded
500/mL for 3 consecutive days. ES was diagnosed if pa-
tients presented with 2 or more of the following symp-
toms within 7 days before neutrophil engraftment: (1)
fever of unknown origin .38.0C with no infectious
agent or other reason detectable, (2) erythematous
skin rash not because of drug reactions or viral infec-
tion, (3) weight gain of $5% and albumin drop to
#90% of pretransplant levels, and (4) pulmonary
symptoms with dyspnea, hypoxia, and pulmonary infil-
trates on a chest X-ray.
Statistical Analysis
Statistical analysis comparing 2 groups was per-
formed using 2  2 contingency tables and Fisher’s ex-
act test for count data (one sided). For survival estimates
a Kaplan-Meier life table analysis and a Mantel-
Haenszel log rank test were used to compare the timevariables between both groups. Differences were con-
sidered significant at P\ .05. The following software
was used for statistical analyses: ‘‘R’’ version 2.6.1
(R development core team, Vienna, Austria) and Prism,
version 3.0 (GraphPad Software, San Diego, CA).
RESULTS
Incidence of and Symptoms Associated with ES
To assess the incidence of ES in pediatric alloge-
neic HSCT recipients we classified the patients for
the presence of ES according to the above-mentioned
criteria.
Of the 61 consecutive allogeneic HSCT analyzed,
29 (48%) met the diagnostic criteria for ES with at least
2 symptoms. Fever of otherwise unexplained etiology
was present in 90% of transplantations diagnosed
with ES (26 of 29 patients), an erythematous skin
rash in 72% (21 of 29), weight gain/albumin drop in
66% (19 of 29) and pulmonary symptoms in 24%
(7 of 29) (Figure 1A). Incidence of these symptoms in
all transplantations was: fever 64% (39 of 61), skin
rash 38% (23 of 61), weight gain/albumin drop 38%
(23 of 61), and pulmonary symptoms 11% (7 of 61).
Other symptoms included in the criteria suggested by
Spitzer [1] were less frequent: hepatic dysfunction
8% (5 of 61), renal dysfunction 3% (2 of 61), and en-
cephalopathy in 0% (Figure 1A). One patient devel-
oped acute respiratory distress syndrome requiring
mechanical ventilation. Previous reports had indicated
that G-CSF administration would predispose to an in-
creased rate of pulmonary complications after HSCT,
which was not significant in the population analyzed
here (Figure 1B; P5 .09). Median onset of ES was ob-
served after 16 days (range: 7-24). The median time to
neutrophil recovery was 18 days (8-30) for the entire
cohort and 18 (8-28) and 19 (10-30) for patients
with or without ES respectively (Figure 2).
In summary, these data demonstrate that ES repre-
sents a frequent complication of HSCT in pediatric
patients.
Influence of Transplant andDiseaseCharacteristics
on the Incidence of ES
Previous studies in adult patients had identified pe-
ripheral blood as stem cell source, higher number of
cells infused, certain underlying diseases (breast can-
cer), therapy with amphotericin B, application of G-
CSF, and early recovery of neutrophil counts as risk
factors associated with the development of ES [17].
We therefore analyzed the influence of these factors
on the incidence of ES in our pediatric transplant co-
hort. As the types of underlying diseases were very var-
iable (Table 1), we categorized them as either
malignant or nonmalignant.
In a univariate analysis the incidence of ES was not
different depending on whether patients had received
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Figure 1. Symptoms associated with ES. (A) Frequency of diagnostic symptoms in patients diagnosed with ES. The gray bars represent symp-
toms included in the diagnostic criteria used in this study. (B) Association of pulmonary symptoms with G-CSF application.bone marrow or peripheral blood (24 of 50 versus 5 of
11; P5 .68), T cell depleted or not (5 of 11 versus 24 of
50; P 5 .57), from an unrelated or related donor (8 of
19 versus 21 of 42; P5 .38), or whether they had a ma-
lignant or nonmalignant underlying disease (22 of 44
versus 7 of 17; P5 .37) (Table 2a). There was a nonsig-
nificant trend toward a higher incidence associated
with a neutrophil recovery on or before day 14 after
transplantation (11 of 18 versus 18 of 43; P 5 .14)
and whether patients were on amphotericin B therapy
(25 of 46 versus 4 of 15; P5 .06). The kinetics of neu-
trophil recovery in patients with or without ES are dis-
played in Figure 2. There was, however, a significant
influence of G-CSF application with 12 of 17 patients
developing ES versus 17 of 44 without G-CSF (P 5
.02). Likewise, a graft containing $7  108 mononu-
clear cells (MNC) was associated with a significantly
increased incidence of ES in 16 of 22 (73%) patients
compared to 8 of 28 (29%) with an MNC count of
\7  108 (P5 .002). Using a multiple logistic regres-
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Figure 2. Neutrophil recovery kinetics in ES. Cumulative incidence
of time to neutrophil recovery in transplants with (ES) and without
ES (no ES) (n 5 61; P 5 .15).sion analysis, amphotericin B (P5 .009) and MNC$7
 108 (P 5 .004) were significant risk factors, whereas
G-CSF treatment was not (P 5 .35). These data are
summarized in Table 2A. A 7-way multiple logistic re-
gression model was built and a minimal model ob-
tained by stepwise regression. The reduced model
showed a trend toward a higher incidence of ES with
an underlying malignant disease (P 5 .12), and again,
a significant influence of amphotericin B therapy
(P 5 .005) and MNC $7  108 (P 5 .002) (Table 2B).
T cell depletion was excluded from the multiway anal-
ysis because of its perfect correlation with very low
MNC values and with G-CSF therapy. This observa-
tion is easily explained by the fact that all T cell deple-
tions were carried out by CD34 positive selection,
resulting in extremely low MNC counts, and that all
these patients had received G-CSF a priori.
Taken together, a higher MNC count of the graft
and G-CSF application were significant risk factors for
developing ES in a univariate analysis in this pediatric
transplant cohort, while amphotericin B therapy and
higher MNC were significant risk factors in a multiple
logistic regression analysis.
ES and GVHD
ES as an early complication of HSCT has been hy-
pothesized to be the clinical correlate of a cytokine
storm during engraftment. The release of high
amounts of pro-inflammatory cytokines is also widely
accepted to be 1 of the determining factors during
the early phase of GVHD after HSCT [15]. We there-
fore analyzed whether the occurrence of ES was asso-
ciated with an increased incidence of GVHD in
pediatric HSCT.
However, there was no difference in the incidence
of aGVHD of any grade in patients with or without ES
(17 of 29 versus 15 of 32; P5 .25) and a nonsignificant
trend toward a higher rate of chronic GVHD
442 I. Schmid et al.Table 2a. Influence of transplant and disease characteristics on the incidence of ES
Overall incidence of ES
Incidence with respect to: 29/61 (48%) Fisher’s exact test Multiple logistic regression
Graft source BM 24/50 (48%) PB 5/11 (45%) p50.68 p50.99
T-cell depletion yes 5/11 (45%) no 24/50 (48%) p50.57 §§
Donor unrelated 8/19 (42%) related 21/42 (50%) p50.38 p50.92
Underlying disease non-malignant 7/17 (41%) malignant 22/44 (50%) p50.37 p50.11
Neutrophil recovery after d14 18/43 (42%) until d14 11/18 (61%) p50.14 p50.22
Amphotericin B therapy no 4/15 (27%) yes 25/46 (54%) p50.06 p50.009
G-CSF therapy no 17/44 (39%) yes 12/17 (71%) p50.02 p50.35
MNC \7*108 8/28 (29%) 7*108 16/22 (73%) p50.002§ p50.004
BM: bone marrow, PB: peripheral blood, G-CSF: granulocyte colony stimulating factor, MNC: mononuclear cell count of the graft.
§transplants with T-cell depletion were excluded from MNC analysis, due to their extremely low MNC count caused by graft manipulation.
§§transplants with T-cell depletion were excluded from the multiple logistic regression analysis due to perfect correlation with MNC\7*108
and G-CSF use.(cGVHD) (7 of 21 versus 4 of 28; P5 .11). These data
are summarized in Table 3.
In summary, we could not demonstrate a correla-
tion between ES and GVHD in this study.
Outcome of ES
Because earlier studies had revealed a negative im-
pact of ES on survival after allogeneic HSCT in adults
as well as autologous transplantation in children be-
cause of an increased rate of TRM [8,20], we tested
whether there was any discernible effect of ES on over-
all survival (OS) and TRM in our study cohort.
However, after a median follow-up of 9.5 years
(range: 5.9-17.4) OS did not differ after transplanta-
tions complicated by ES compared to such without
ES (Figure 3A; P5 .53). Likewise, TRM was identical
in both groups (Figure 3B; P 5 .65).
Taken together, we could not identify any impact
of the occurrence of ES on OS or TRM.
DISCUSSION
This study represents, to our knowledge, the first
published analysis to investigate the incidence, predis-
posing factors, nonrelapse mortality, and survival of ES
in pediatric allogeneic HSCT with a median follow-up
of 9.5 years (range: 5.9-17.4). Of the 61 consecutive
transplantations 48% met our diagnostic criteria for
ES ($2 of the following symptoms: fever, skin rash,
Table 2B.Minimal Multiple Logistic Regression Analysis
Predisposing Factor:
Underlying disease malignant P 5 .12
Amphotericin B therapy yes P 5 .005
MNC $7  108 P 5 .002
Multiple logistic regression analysis was performed including 7 fac-
tors (graft source, donor, underlying disease, neutrophil recov-
ery, amphotericin B therapy, G-CSF therapy, and MNC). A
minimal model was obtained by stepwise regression.weight gain/albumin drop, pulmonary symptoms). In
2001, Spitzer [1] proposed specific diagnostic criteria
for ES. As major criteria, he suggested (1) temperature
$38.3C with no infectious etiology, (2) erythematous
rash involving .25% of body surface area and not at-
tributable to a medication, and (3) noncardiogenic pul-
monary edema manifested by diffuse pulmonary
infiltrates consistent with this diagnosis, accompanied
by hypoxia. As minor criteria, he suggested (1) hepatic
dysfunction with either total bilirubin $2 mg/dL or
transaminase levels$2 times normal, (2) renal insuffi-
ciency with serum creatinine $2 times baseline, (3)
weight gain $2.5% of baseline body weight, and (4)
transient encephalopathy unexplainable by other
causes [1]. A diagnosis of ES would be established by
the presence of all 3 major criteria or 2 major criteria
and 1 or more minor criteria. Although these criteria
are somewhat more stringent than the ones we used
in this study, they encompass most of the diagnostic
items that we used. However, we do deem our criteria
to better reflect the clinical situation in pediatric pa-
tients as the incidence of renal or hepatic dysfunction
as well as encephalopathy is rather low in children
(Figure 1A). According to the Spitzer [1] criteria, the
incidence of ES in our cohort would have been 20%
(12 of 61).
Before ES was recognized as an independent entity
of clinical symptoms it was often described as an early
manifestation of a graft-versus-host reaction in alloge-
neic transplantation [21]. However, this does not ex-
plain the same high incidence of ES with a nearly
identical clinical presentation in autologous transplan-
tation in a study by Cahill et al. [5]. One could argue
Table 3. Incidence of GVHD in Patients with ES
ES no ES
GVHD
acute 17/29 (59%) 15/32 (47%) P 5 .25
chronic 7/21 (33%) 4/28 (14%) P 5 .11
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Figure 3. OS and TRM. OS (A) and TRM (B) in patients with (ES) and without (no ES) engraftment syndrome.that in the allogeneic setting early GVHD may be mis-
diagnosed as ES, but in this case one would expect
a higher incidence of later GVHD manifestations in
patients diagnosed with ES. In our study we could
not identify an association between ES and the subse-
quent development of aGVHD or cGVHD, adding
further evidence that this syndrome occurs indepen-
dently of graft-versus-host pathology. With cytokine
release being a hallmark both of early GVHD develop-
ment [15] as well as ES [5], however, one can still spec-
ulate that there may be a certain overlap between both
syndromes. Clinical situations might occur where a dif-
ferentiation between the 2 might prove difficult, such
as when rash develops before engraftment without fur-
ther indication of GVHD. In these cases either addi-
tional symptoms fulfilling the above-mentioned
criteria for ES or skin biopsies might help to draw a dis-
tinction. Routine skin biopsies for rash were not per-
formed in this study.
Sinusoidal obstruction syndrome (SOS) is another
condition after HSCT that might sometimes be con-
fused with ES, especially because some criteria for
the diagnosis of both overlap, such as increase in serum
bilirubin and weight gain. However, there are also cri-
teria such as rash or fever for ES or right upper quad-
rant pain for SOS that can help to differentiate
between the 2. This is further illustrated by the fact
that in this cohort only 2 of the ES patients were also
diagnosed with SOS using the Seattle criteria [22],
whereas this was the case in 1 patient in the group
without ES.
As noted above, various predisposing factors for
ES had been identified in previous studies. Most of
them have only been found in some studies, likely
reflecting the variable criteria used for diagnosing
ES. One of the significant factors identified by univar-
iate analysis in this study was granulocyte-colony stim-
ulating factor (G-CSF) application, which was also
found in the study by Lee et al. [2]. G-CSF application
also lead to a nonsignificant increase in the rate of pul-
monary complications. It can be speculated that the
neutrophils further triggered by G-CSF during recov-
ery are trapped in the small pulmonary vessels as a con-sequence of cytokine release, endothelial lung damage
by cytotoxic drugs, and previous radiotherapy and de-
fective phagocytosis. The other significant risk factor
in univariate analysis was a high MNC count, which
had also been identified in 2 other adult studies [3,4].
When we analyzed our data in a multiple logistic re-
gression model followed by an automated stepwise re-
gression procedure, amphotericin B therapy evolved as
a significant risk factor. MNC count was still signifi-
cant, but G-CSF treatment was not anymore. This is
very likely because of the fact that all patients receiving
CD34 positive selected grafts had received G-CSF
a priori, and these data sets had to be removed from
this statistical analysis, thereby likely reducing the pos-
sible influence of G-CSF treatment in this analysis.
The incidence of ES was not affected by the source
of stem cells, T cell depletion, type of donor, underly-
ing disease, and time of neutrophil recovery, indicating
that in the pediatric allogeneic transplant setting other
factors may be important in the development of ES
than in adult or autologous transplantation. In the
only prospective study in pediatric autologous
HSCT, high numbers of CD341 cells/kg infused, chil-
dren transplanted in an early phase, the type of malig-
nancy (solid tumor), and a conditioning regimen other
than busulfan based were significantly associated with
ES in a multivariate analysis [13].
ES was determined to be the most important cause
of TRM in the study by Foncillas et al. [20], which an-
alyzed autologous transplantation in children, a situa-
tion in which TRM is and should be a very rare
event. Therefore, this finding cannot be compared to
the fact that diagnosis of ES did not translate into
a higher rate of TRM in the allogeneic setting in this
study. There was also no difference in overall survival
in the group diagnosed with ES. However, because
of the retrospective nature of this study we cannot ex-
clude an influence of ES-directed treatment on the
outcome of our patients. Steroids are commonly used
to treat ES, thereby utilizing its immunosuppressive
and anti-inflammatory effect. However, there is no
agreement on the most effective dose [2,6,11] and
whether the clinical outcome is influenced by this
444 I. Schmid et al.treatment [11]. However, steroids do seem to have an
effect on ES, because steroid prophylaxis (0.5 mg/kg/
day) from day 14 to 114 significantly decreased the
incidence of ES in adults by almost 10-fold following
autologous PBSCT without increasing the risk of in-
fection [23]. In our patient group, empirical treatment
with prednisolone in standard doses (2 mg/kg/day) was
administered in 18 of 29 (62%) of ES patients at the
time of diagnosis of ES and seemed to be effective, as
no patient died as a direct consequence of ES-related
morbidity. Usually within 3 days after initiation of
the steroid therapy the clinical condition improved
dramatically, so that we could rapidly taper the steroid
dose. However, because of the possible detrimental ef-
fects of steroid therapy after HSCT such as increased
risk of infection and abrogation of graft-versus-tumor
reaction, we clearly need prospective studies to evalu-
ate the role of steroids in the treatment of ES.
In summary, we found a high incidence of ES in
children undergoing allogeneic HSCT with G-CSF
use, amphotericin B treatment and a high MNC count
of the graft as significant risk factors. ES had no effect on
survival and TRM in this cohort. Further studies to elu-
cidate the pathophysiology of ES and common diagnos-
tic criteria to describe this clinical entity after HSCT are
needed to differentiate ES from GVHD, SOS, and
infections. Steroids seem to be an effective therapy for
ES, but in the future it will be necessary to investigate
the effects of steroid therapy without reducing antitu-
mor activity and increasing infectious complications.
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